Drug Trial Radar · NCT02180217
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Last checked: Nov 19, 2026Latest source record: Jan 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
137
Actual
Start
Oct 6, 2014
Primary completion
Feb 21, 2018
Study completion Dec 4, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aimed to confirm long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease. It was a pivotal trial which supported the registration of LCI699 for the treatment of patients with Cushing's disease in the US and the EU. This is a phase lll, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period which evaluated the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease.
Conditions
- Cushings Disease
Interventions
osilodrostatDrug
Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
LCI699 matching placeboDrug
Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Primary Efficacy Responder at Week 34 by Randomized Treatment and StrataTime frame: Week 34 (8 weeks)
Locations
60 sites in 19 countries. Site status is shown where the registry gives one.
University of Colorado Hospital SC - LCI699C2301
Aurora, Colorado
Emory University School of Medicine G2304 - C2301
Atlanta, Georgia
Northwestern University SC - LCI699C2301
Chicago, Illinois
The Johns Hopkins University School of Medicine Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital Neuroendocrine Unit
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Mount Sinai School of Medicine SC - LCI699C2301
New York, New York
Columbia University Medical Center New York Presbyterian SC - LCI699C2301
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Oregon Health and Science University SC LCI699C2301
Portland, Oregon
University of Pennsylvania Clinical Studies Unit Unniv SC
Philadelphia, Pennsylvania
Medical College of Wisconsin MCW 2
Milwaukee, Wisconsin
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Sherbrooke, Quebec, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, Beijing Municipality, China
Novartis Investigative Site
Chengdu, Sichuan, China
Novartis Investigative Site
Cali, Colombia
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Erlangen, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
New Delhi, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Chandigarh, Punjab, India
Novartis Investigative Site
Vellore, Tamil Nadu, India
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Messina, ME, Italy
Novartis Investigative Site
Milan, MI, Italy
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.